The ferrous-dioxygen intermediate in human cytochrome P450 3A4 - Substrate dependence of formation and decay kinetics

被引:70
|
作者
Denisov, Ilia G.
Grinkova, Yelena V.
Baas, Bradley J.
Sligar, Stephen G.
机构
[1] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA
[2] Univ Illinois, Dept Chem, Urbana, IL 61801 USA
[3] Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA
[4] Univ Illinois, Coll Med, Urbana, IL 61801 USA
关键词
D O I
10.1074/jbc.M605511200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The oxy-ferrous complex is the first of three branching intermediates in the catalytic cycle of cytochrome P450, in which the total efficiency of substrate turnover is curtailed by the side reaction of autoxidation. For human membrane-bound cytochromes P450, the oxy complex is believed to be the primary source of cytotoxic superoxide and peroxide, although information on the properties and stability of this intermediate is lacking. Here we document stopped-flow spectroscopic studies of the formation and decay of the oxy-ferrous complex in the most abundant human cytochrome P450 (CYP3A4) as a function of temperature in the substrate-free and substrate-bound form. CYP3A4 solubilized in purified monomeric form in nanoscale POPC bilayers is functionally and kinetically homogeneous. In substrate-free CYP3A4, the oxy complex is extremely unstable with a half-life of similar to 30msat 5 degrees C. Saturation with testosterone or bromocriptine stabilizes the oxy-ferrous intermediate. Comparison of the autoxidation rates with the available data on CYP3A4 turnover kinetics suggests that the oxy complex may be an important route for uncoupling.
引用
收藏
页码:23313 / 23318
页数:6
相关论文
共 50 条
  • [31] Kohonen maps for prediction of binding to human cytochrome P450 3A4
    Balakin, KV
    Ekins, S
    Bugrim, A
    Ivanenkov, YA
    Korolev, D
    Nikolsky, YV
    Skorenko, AV
    Ivashchenko, AA
    Savchuk, NP
    Nikolskaya, T
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (10) : 1183 - 1189
  • [32] Chromatographic assays of drug oxidation by human cytochrome P450 3A4
    Christal D Sohl
    Qian Cheng
    F Peter Guengerich
    Nature Protocols, 2009, 4 : 1252 - 1257
  • [33] Role of human cytochrome p450 3A4 in metabolism of medroxyprogesterone acetate
    Kobayashi, K
    Mimura, N
    Fujii, H
    Minami, H
    Sasaki, Y
    Shimada, N
    Chiba, K
    CLINICAL CANCER RESEARCH, 2000, 6 (08) : 3297 - 3303
  • [34] Cooperativity in cytochrome P450 3A4 -: Linkages in substrate binding, spin state, uncoupling, and product formation
    Denisov, Ilia G.
    Baas, Bradley J.
    Grinkova, Yelena V.
    Sligar, Stephen G.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (10) : 7066 - 7076
  • [35] Expression of human cytochrome p450 3A4 gene in Schizosaccharomyces pombe
    Palabiyik, Bedia
    Karaer, Semian
    Arda, Nazli
    Toker, Sidika Erturk
    Temizkan, Guler
    Kelly, Steven
    Sarikaya, Aysegul Topal
    BIOLOGIA, 2008, 63 (03) : 450 - 454
  • [36] Kinetics of substrate binding to human Cytochrome P450 3A4: A study with Fluorol-7GA, a fluorescent allosteric ligand
    Rumfeldt, Jessica Anne Osborne
    Halpert, James R.
    Davydov, Dmitri R.
    FASEB JOURNAL, 2010, 24
  • [37] Interaction of methadone with substrates of human hepatic cytochrome P450 3A4
    Iribarne, C
    Dreano, Y
    Bardou, LG
    Menez, JF
    Berthou, F
    TOXICOLOGY, 1997, 117 (01) : 13 - 23
  • [38] Metabolism of organochlorine pesticides: The role of human cytochrome P450 3A4
    Mehmood, Z
    Williamson, MP
    Kelly, DE
    Kelly, SL
    CHEMOSPHERE, 1996, 33 (04) : 759 - 769
  • [39] Multiple substrate binding by cytochrome P450 3A4:: Estimation of the number of bound substrate molecules
    Kapelyukh, Yury
    Paine, Mark J. I.
    Marechal, Jean-Didier
    Sutcliffe, Michael J.
    Wolf, C. Roland
    Roberts, Gordon C. K.
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (10) : 2136 - 2144
  • [40] Multivariate modeling of cytochrome P450 3A4 inhibition
    Kriegl, JM
    Eriksson, L
    Arnhold, T
    Beck, B
    Johansson, E
    Fox, T
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 24 (05) : 451 - 463